2010
DOI: 10.1089/ten.tea.2009.0710
|View full text |Cite
|
Sign up to set email alerts
|

Adipose-Derived Mesenchymal Stem Cells Treated with Growth Differentiation Factor-5 Express Tendon-Specific Markers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

14
131
3
2

Year Published

2013
2013
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 137 publications
(150 citation statements)
references
References 47 publications
14
131
3
2
Order By: Relevance
“…For example, patient's own multipotent mesenchymal stem cells (MSCs) can be isolated from adipose tissue, expanded ex vivo, and transplanted to the defect site using biomaterial scaffold as a carrier (Mesimaki et al, 2009;Thesleff et al, 2011). Among adult stem cells, human adipose stem cells (hASCs) are readily available multipotent cells having the potential to differentiate into lineages of mesenchymal tissues, including bone, cartilage, fat, tendon, muscle, and marrow stroma (Zuk et al, 2001;Zuk et al, 2002;Park et al, 2010;Choi et al, 2012). The osteogenic capacity of ASCs has been demonstrated in both in vitro (Zuk et al, 2002;De Girolamo et al, 2007) and in vivo studies (Cowan et al, 2004;Hicok et al, 2004;Hattori et al, 2006;Di Bella et al, 2008;Behr et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…For example, patient's own multipotent mesenchymal stem cells (MSCs) can be isolated from adipose tissue, expanded ex vivo, and transplanted to the defect site using biomaterial scaffold as a carrier (Mesimaki et al, 2009;Thesleff et al, 2011). Among adult stem cells, human adipose stem cells (hASCs) are readily available multipotent cells having the potential to differentiate into lineages of mesenchymal tissues, including bone, cartilage, fat, tendon, muscle, and marrow stroma (Zuk et al, 2001;Zuk et al, 2002;Park et al, 2010;Choi et al, 2012). The osteogenic capacity of ASCs has been demonstrated in both in vitro (Zuk et al, 2002;De Girolamo et al, 2007) and in vivo studies (Cowan et al, 2004;Hicok et al, 2004;Hattori et al, 2006;Di Bella et al, 2008;Behr et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…Bioactive glass and biphasic calcium phosphate, both biomaterials currently used in craniomaxillofacial (Peltola et al, 2006;Peltola et al, 2008;Frenken et al, 2010;Clozza et al, 2012b) and orthopaedic surgery (Lindfors et al, 2010;Garrido et al, 2011), were compared as prospective carriers for hASCs in the current study. Synthetic bioceramics are among the most promising biomaterials for the use of bone tissue engineering largely due to their capacity to form bone-like apatite layers in contact with physiological fluids, a reaction which facilitates their strong bonding to bone (Hench, 1998;Kokubo et al, 2003).…”
Section: Introductionmentioning
confidence: 99%
“…Adipose tissue is obtained from different organs such as abdominal subcutaneous, inguinal, kidney, or epididymis under sterile conditions (Banas et al 2007;Zaminy et al 2008;Park et al 2010;Ren et al 2012;Ahmad and Shakori 2013;Huangm et al 2013). Adipose tissues are transported to the laboratory in phosphate-buffered saline (PBS) solution or Dulbecco's Modified Eagle's Medium (DMEM) containing antibiotics within 2 h postsurgery for further procedures (Banas et al 2007;Ahmad and Shakori 2013).…”
Section: Adscs Harvesting Isolation and Culturingmentioning
confidence: 99%
“…To isolate ADSCs, the sample is spun at 2000 rpm for 5 min to collect the fat tissue pieces. The fat pieces are washed extensively with sterile equal volumes of PBS three times and treated with 0.01% (Park et al 2010 (Fig.1). Enzyme activity is neutralized with DMEM high or low glucose containing 10% fetal bovine serum (FBS) and centrifuged at 1200 rpm for 10 min to obtain a pellet.…”
Section: Adscs Harvesting Isolation and Culturingmentioning
confidence: 99%
“…Numerosos trabajos apuntan hacia el uso de las células madre mesenquimales como principal fuente celular utilizando sobre todo células madre provenientes de la médula ósea [60], del tejido adiposo [61] o del líquido sinovial [62]. Pacini et al [63], demostraron que la inyección de una suspensión de células madre autólogas indiferenciadas provenientes de médula ósea en una lesión del tendón flexor digital equino, daba lugar a una recuperación clínica significativa.…”
Section: A) Fuentes Celulares Y Terapia Celularunclassified